{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:20:43Z","timestamp":1789690843871,"version":"4.0.1"},"reference-count":159,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)\u2014previously described as nonalcoholic fatty liver disease\u2014continues to rise globally. Despite this, therapeutic measures for MASLD remain limited. Recently, there has been a growing interest in the gut microbiome's role in the pathogenesis of MASLD. Understanding this relationship may allow for the administration of therapeutics that target the gut microbiome and\/or its metabolic function to alleviate MASLD development or progression. This review will discuss the interplay between the gut microbiome's structure and function in relation to the development of MASLD, assess the diagnostic yield of gut microbiome-based signatures as a noninvasive tool to identify MASLD severity, and examine current and emerging therapies targeting the gut microbiome\u2013liver axis.<\/jats:p>","DOI":"10.1055\/a-2438-4383","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T23:29:07Z","timestamp":1728602947000},"page":"457-473","source":"Crossref","is-referenced-by-count":11,"title":["Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1055","volume":"44","author":[{"given":"Salim","family":"Maher","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, St George Hospital, Sydney, Australia"},{"name":"School of Clinical Medicine, UNSW Medicine & Health, St George & Sutherland Clinical Campuses"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashi","family":"Rajapakse","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, UNSW Medicine & Health, St George & Sutherland Clinical Campuses"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"El-Omar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, St George Hospital, Sydney, Australia"},{"name":"School of Clinical Medicine, UNSW Medicine & Health, St George & Sutherland Clinical Campuses"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany","family":"Zekry","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, St George Hospital, Sydney, Australia"},{"name":"School of Clinical Medicine, UNSW Medicine & Health, St George & Sutherland Clinical Campuses"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Z Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"09","key":"ref2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"K Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"C Estes","year":"2018","journal-title":"J Hepatol"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"M E Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nature06244","article-title":"The human microbiome project","volume":"449","author":"P J Turnbaugh","year":"2007","journal-title":"Nature"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrmicro1978","article-title":"Worlds within worlds: evolution of the vertebrate gut microbiota","volume":"6","author":"R E Ley","year":"2008","journal-title":"Nat Rev Microbiol"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nri.2017.7","article-title":"Dysbiosis and the immune system","volume":"17","author":"M Levy","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","article-title":"Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice","volume":"62","author":"T Le Roy","year":"2013","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"32002","DOI":"10.1038\/srep32002","article-title":"Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease","volume":"6","author":"B Wang","year":"2016","journal-title":"Sci Rep"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"J Boursier","year":"2016","journal-title":"Hepatology"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40168-019-0704-8","article-title":"Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health","volume":"7","author":"K Oliphant","year":"2019","journal-title":"Microbiome"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/hep.29892","article-title":"Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD","volume":"68","author":"C Caussy","year":"2018","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"19076","DOI":"10.1038\/srep19076","article-title":"Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults","volume":"6","author":"Y M Chen","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1111\/liv.14696","article-title":"Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"40","author":"T JI De Munck","year":"2020","journal-title":"Liver Int"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jcmgh.2015.01.001","article-title":"Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability","volume":"1","author":"J Luther","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"L Miele","year":"2009","journal-title":"Hepatology"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.3390\/cells10113164","article-title":"High-fat, western-style diet, systemic inflammation, and gut microbiota: a narrative review","volume":"10","author":"I J Malesza","year":"2021","journal-title":"Cells"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"e12191","DOI":"10.1371\/journal.pone.0012191","article-title":"High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse","volume":"5","author":"S Ding","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.3390\/cells10113168","article-title":"Effect of a high-fat diet on the small-intestinal environment and mucosal integrity in the gut-liver axis","volume":"10","author":"T Nakanishi","year":"2021","journal-title":"Cells"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"e34233","DOI":"10.1371\/journal.pone.0034233","article-title":"Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice","volume":"7","author":"Y Y Lam","year":"2012","journal-title":"PLoS One"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/gutjnl-2012-304119","article-title":"Western diet induces dysbiosis with increased E. coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation","volume":"63","author":"M Martinez-Medina","year":"2014","journal-title":"Gut"},{"issue":"22","key":"ref23","doi-asserted-by":"crossref","first-page":"9066","DOI":"10.1073\/pnas.1219451110","article-title":"Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity","volume":"110","author":"A Everard","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"19032","DOI":"10.1038\/srep19032","article-title":"Western diet induces a shift in microbiota composition enhancing susceptibility to adherent-invasive E. coli infection and intestinal inflammation","volume":"6","author":"A Agus","year":"2016","journal-title":"Sci Rep"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/hep.30652","article-title":"fructose promotes leaky gut, endotoxemia, and liver fibrosis through ethanol-inducible cytochrome P450-2E1-mediated oxidative and nitrative stress","volume":"73","author":"Y E Cho","year":"2021","journal-title":"Hepatology"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gutjnl-2014-308778","article-title":"Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology","volume":"65","author":"M C Dao","year":"2016","journal-title":"Gut"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study","volume":"25","author":"C Depommier","year":"2019","journal-title":"Nat Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3389\/fmicb.2017.01804","article-title":"Protective effect of Akkermansia muciniphila against immune-mediated liver injury in a mouse model","volume":"8","author":"W Wu","year":"2017","journal-title":"Front Microbiol"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1038\/emm.2017.282","article-title":"Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions","volume":"50","author":"C Chelakkot","year":"2018","journal-title":"Exp Mol Med"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/jcpe.13214","article-title":"Akkermansia muciniphila reduces Porphyromonas gingivalis-induced inflammation and periodontal bone destruction","volume":"47","author":"O Huck","year":"2020","journal-title":"J Clin Periodontol"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12929-023-00935-1","article-title":"Akkermansia muciniphila and its membrane protein ameliorates intestinal inflammatory stress and promotes epithelial wound healing via CREBH and miR-143\/145","volume":"30","author":"H Wade","year":"2023","journal-title":"J Biomed Sci"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1128\/AEM.04050-14","article-title":"Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer","volume":"81","author":"J Reunanen","year":"2015","journal-title":"Appl Environ Microbiol"},{"issue":"07","key":"ref33","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/oby.21122","article-title":"Effects of dietary fat profile on gut permeability and microbiota and their relationships with metabolic changes in mice","volume":"23","author":"Y Y Lam","year":"2015","journal-title":"Obesity (Silver Spring)"},{"issue":"39","key":"ref34","doi-asserted-by":"crossref","first-page":"37041","DOI":"10.1074\/jbc.M305213200","article-title":"Reciprocal modulation of toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase\/AKT by saturated and polyunsaturated fatty acids","volume":"278","author":"J Y Lee","year":"2003","journal-title":"J Biol Chem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2015.11.015","article-title":"Saturated fatty acids trigger TLR4-mediated inflammatory response","volume":"244","author":"D M Rocha","year":"2016","journal-title":"Atherosclerosis"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12929-018-0483-8","article-title":"Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis","volume":"25","author":"L C-H Yu","year":"2018","journal-title":"J Biomed Sci"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"1782157","DOI":"10.1080\/19490976.2020.1782157","article-title":"Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans","volume":"12","author":"L Maccioni","year":"2020","journal-title":"Gut Microbes"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12885-018-4484-5","article-title":"Increased systemic zonula occludens 1 associated with inflammation and independent biomarker in patients with hepatocellular carcinoma","volume":"18","author":"A K Ram","year":"2018","journal-title":"BMC Cancer"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ajpath.2012.10.014","article-title":"Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14","volume":"182","author":"S Guo","year":"2013","journal-title":"Am J Pathol"},{"issue":"10","key":"ref40","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.4049\/jimmunol.1402598","article-title":"Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88","volume":"195","author":"S Guo","year":"2015","journal-title":"J Immunol"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/19490976.2019.1629235","article-title":"Lipopolysaccharides modulate intestinal epithelial permeability and inflammation in a species-specific manner","volume":"11","author":"M Stephens","year":"2020","journal-title":"Gut Microbes"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.ajpath.2017.08.005","article-title":"Lipopolysaccharide-induced increase in intestinal epithelial tight permeability is mediated by toll-like receptor 4\/myeloid differentiation primary response 88 (MyD88) activation of myosin light chain kinase expression","volume":"187","author":"M Nighot","year":"2017","journal-title":"Am J Pathol"},{"issue":"53","key":"ref43","doi-asserted-by":"crossref","first-page":"55506","DOI":"10.1074\/jbc.M408822200","article-title":"A differentiation-dependent splice variant of myosin light chain kinase, MLCK1, regulates epithelial tight junction permeability","volume":"279","author":"D R Clayburgh","year":"2004","journal-title":"J Biol Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"55506","DOI":"10.3389\/fendo.2021.770986","article-title":"Endotoxins and non-alcoholic fatty liver disease","volume":"12","author":"T Kessoku","year":"2021","journal-title":"Front Endocrinol"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.31056","article-title":"Increased liver localization of lipopolysaccharides in human and experimental NAFLD","volume":"72","author":"G Carpino","year":"2020","journal-title":"Hepatology"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"45176","DOI":"10.1038\/srep45176","article-title":"Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia","volume":"7","author":"L Xue","year":"2017","journal-title":"Sci Rep"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3892\/mmr.2014.2995","article-title":"Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model","volume":"11","author":"A Douhara","year":"2015","journal-title":"Mol Med Rep"},{"issue":"06","key":"ref48","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"J Mouries","year":"2019","journal-title":"J Hepatol"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"J P Arab","year":"2017","journal-title":"Hepatology"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"A Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"D W Russell","year":"2003","journal-title":"Annu Rev Biochem"},{"issue":"08","key":"ref52","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"C Thomas","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"05","key":"ref53","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"H Wang","year":"1999","journal-title":"Mol Cell"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mce.2012.05.004","article-title":"FXR signaling in the enterohepatic system","volume":"368","author":"T Matsubara","year":"2013","journal-title":"Mol Cell Endocrinol"},{"issue":"03","key":"ref55","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"T T Lu","year":"2000","journal-title":"Mol Cell"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"D J Parks","year":"1999","journal-title":"Science"},{"issue":"35","key":"ref57","doi-asserted-by":"crossref","first-page":"31441","DOI":"10.1074\/jbc.M200474200","article-title":"Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity","volume":"277","author":"J Yu","year":"2002","journal-title":"J Biol Chem"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"M Mueller","year":"2015","journal-title":"J Hepatol"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"S I Sayin","year":"2013","journal-title":"Cell Metab"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MEG.0b013e3282f4710a","article-title":"Bile acid levels are increased in the liver of patients with steatohepatitis","volume":"20","author":"M M Aranha","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/gutjnl-2015-310283","article-title":"Microbiota-induced obesity requires farnesoid X receptor","volume":"66","author":"A Pars\u00e9us","year":"2017","journal-title":"Gut"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"C Jiang","year":"2015","journal-title":"J Clin Invest"},{"issue":"10","key":"ref63","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"N Jiao","year":"2018","journal-title":"Gut"},{"issue":"11","key":"ref64","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"B C Ferslew","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"P Puri","year":"2018","journal-title":"Hepatology"},{"issue":"06","key":"ref66","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/hep.32568","article-title":"Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD","volume":"76","author":"E Smirnova","year":"2022","journal-title":"Hepatology"},{"issue":"05","key":"ref67","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3920\/BM2020.0057","article-title":"Short chain fatty acids in human gut and metabolic health","volume":"11","author":"E E Blaak","year":"2020","journal-title":"Benef Microbes"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12964-023-01219-9","article-title":"Short-chain fatty acids in diseases","volume":"21","author":"D Zhang","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"06","key":"ref69","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Q Song","year":"2023","journal-title":"J Hepatol"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s40168-021-01125-7","article-title":"Commensal microbe-derived acetate suppresses NAFLD\/NASH development via hepatic FFAR2 signalling in mice","volume":"9","author":"R Aoki","year":"2021","journal-title":"Microbiome"},{"issue":"12","key":"ref71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0183-1","article-title":"Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression","volume":"50","author":"D Zhou","year":"2018","journal-title":"Exp Mol Med"},{"issue":"04","key":"ref72","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/gidisord5040038","article-title":"Low short-chain-fatty-acid-producing activity of the gut microbiota is associated with hypercholesterolemia and liver fibrosis in patients with metabolic-associated (non-alcoholic) fatty liver disease","volume":"5","author":"X Cao","year":"2023","journal-title":"Gastrointest Disord (Basel)"},{"issue":"07","key":"ref73","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3390\/nu12072127","article-title":"Circulating short-chain fatty acids are positively associated with adiposity measures in Chinese adults","volume":"12","author":"Y Wang","year":"2020","journal-title":"Nutrients"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1038\/nutd.2014.23","article-title":"Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans","volume":"4","author":"J Fernandes","year":"2014","journal-title":"Nutr Diabetes"},{"issue":"05","key":"ref75","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1017\/S0007114512002723","article-title":"Higher level of faecal SCFA in women correlates with metabolic syndrome risk factors","volume":"109","author":"T FS Teixeira","year":"2013","journal-title":"Br J Nutr"},{"issue":"12","key":"ref76","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/ijo.2014.46","article-title":"Evidence for greater production of colonic short-chain fatty acids in overweight than lean humans","volume":"38","author":"S Rahat-Rozenbloom","year":"2014","journal-title":"Int J Obes (Lond)"},{"issue":"01","key":"ref77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/nu11010051","article-title":"Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors","volume":"11","author":"J de la Cuesta-Zuluaga","year":"2018","journal-title":"Nutrients"},{"issue":"01","key":"ref78","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"J Behary","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"ref79","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease","volume":"6","author":"M Rau","year":"2018","journal-title":"United European Gastroenterol J"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.13500","article-title":"The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease","volume":"21","author":"E S Chambers","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"03","key":"ref81","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3892\/etm.2022.11536","article-title":"A potential link between plasma short-chain fatty acids, TNF-\u03b1 level and disease progression in non-alcoholic fatty liver disease: a retrospective study","volume":"24","author":"J Xiong","year":"2022","journal-title":"Exp Ther Med"},{"key":"ref82","first-page":"47","article-title":"Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions","volume":"7","author":"F MF Elshaghabee","year":"2016","journal-title":"Front Microbiol"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"1979883","DOI":"10.1080\/19490976.2021.1979883","article-title":"High alcohol-producing Klebsiella pneumoniae causes fatty liver disease through 2,3-butanediol fermentation pathway in vivo","volume":"13","author":"N-N Li","year":"2021","journal-title":"Gut Microbes"},{"issue":"10","key":"ref84","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/s41591-022-02016-6","article-title":"Microbiome-derived ethanol in nonalcoholic fatty liver disease","volume":"28","author":"A S Meijnikman","year":"2022","journal-title":"Nat Med"},{"issue":"07","key":"ref85","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1007\/s10620-012-2112-9","article-title":"Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD)","volume":"57","author":"V Volynets","year":"2012","journal-title":"Dig Dis Sci"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1279354","DOI":"10.3389\/fcimb.2023.1279354","article-title":"Increased fecal ethanol and enriched ethanol-producing gut bacteria Limosilactobacillus fermentum, Enterocloster bolteae, Mediterraneibacter gnavus and Streptococcus mutans in nonalcoholic steatohepatitis","volume":"13","author":"B Mbaye","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"02","key":"ref87","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"L Zhu","year":"2013","journal-title":"Hepatology"},{"issue":"21","key":"ref88","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/cells11213390","article-title":"Endogenous ethanol and triglyceride production by gut Pichia kudriavzevii, Candida albicans and Candida glabrata yeasts in non-alcoholic steatohepatitis","volume":"11","author":"B Mbaye","year":"2022","journal-title":"Cells"},{"issue":"04","key":"ref89","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","article-title":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae","volume":"30","author":"J Yuan","year":"2019","journal-title":"Cell Metab"},{"issue":"11","key":"ref90","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/jgh.15027","article-title":"Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non-alcoholic fatty liver disease","volume":"35","author":"X Chen","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"01","key":"ref91","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/s41467-023-39028-w","article-title":"Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae","volume":"14","author":"L Gan","year":"2023","journal-title":"Nat Commun"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41420-020-00316-9","article-title":"Mitochondrial dysfunction in fibrotic diseases","volume":"6","author":"X Li","year":"2020","journal-title":"Cell Death Discov"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"115692","DOI":"10.1016\/j.biopha.2023.115692","article-title":"The role of hepatocyte mitochondrial DNA in liver injury","volume":"168","author":"Y Xu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"06","key":"ref94","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/HEP.0000000000000474","article-title":"An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations","volume":"78","author":"R M Carr","year":"2023","journal-title":"Hepatology"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"C Caussy","year":"2019","journal-title":"Nat Commun"},{"issue":"05","key":"ref96","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"R Loomba","year":"2017","journal-title":"Cell Metab"},{"issue":"05","key":"ref97","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A universal gut-microbiome-derived signature predicts cirrhosis","volume":"32","author":"T G Oh","year":"2020","journal-title":"Cell Metab"},{"issue":"10","key":"ref98","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/apt.17236","article-title":"Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis","volume":"56","author":"S R Sharpton","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"ref99","doi-asserted-by":"crossref","first-page":"9385","DOI":"10.1038\/s41598-020-66241-0","article-title":"Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools","volume":"10","author":"S Lang","year":"2020","journal-title":"Sci Rep"},{"issue":"03","key":"ref100","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"F Tacke","year":"2024","journal-title":"J Hepatol"},{"issue":"03","key":"ref101","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"C C Park","year":"2017","journal-title":"Gastroenterology"},{"issue":"04","key":"ref102","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","article-title":"Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"20","author":"K Imajo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"09","key":"ref103","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrgastro.2016.98","article-title":"Understanding the mechanisms of faecal microbiota transplantation","volume":"13","author":"A Khoruts","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"ref104","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.dld.2023.06.015","article-title":"Fecal microbiota transplantation improves hepatic fibro-inflammation via regulating oxidative stress in experimental NASH","volume":"55","author":"D H Lee","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"12","key":"ref105","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/jgh.16359","article-title":"Hepatobiliary and pancreatic: multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota","volume":"38","author":"D Shou","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"01","key":"ref106","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota","volume":"7","author":"D Zhou","year":"2017","journal-title":"Sci Rep"},{"issue":"04","key":"ref107","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.29646","article-title":"Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis","volume":"67","author":"T Garc\u00eda-Lezana","year":"2018","journal-title":"Hepatology"},{"issue":"07","key":"ref108","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial","volume":"115","author":"L Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"ref109","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep4.1601","article-title":"Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis","volume":"4","author":"J J Witjes","year":"2020","journal-title":"Hepatol Commun"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"L Xue","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"02","key":"ref111","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1079\/NRR200479","article-title":"Dietary modulation of the human colonic microbiota: updating the concept of prebiotics","volume":"17","author":"G R Gibson","year":"2004","journal-title":"Nutr Res Rev"},{"issue":"06","key":"ref112","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/nu16060778","article-title":"Prebiotics and probiotics for gastrointestinal disorders","volume":"16","author":"S Rau","year":"2024","journal-title":"Nutrients"},{"issue":"10","key":"ref113","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/gut.28.10.1221","article-title":"Short chain fatty acids in human large intestine, portal, hepatic and venous blood","volume":"28","author":"J H Cummings","year":"1987","journal-title":"Gut"},{"issue":"01","key":"ref114","doi-asserted-by":"crossref","first-page":"1926842","DOI":"10.1080\/19490976.2021.1926842","article-title":"Resistant starch, microbiome, and precision modulation","volume":"13","author":"P A Dobranowski","year":"2021","journal-title":"Gut Microbes"},{"issue":"09","key":"ref115","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations","volume":"35","author":"Y Ni","year":"2023","journal-title":"Cell Metab"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"114300","DOI":"10.1016\/j.biopha.2023.114300","article-title":"Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism","volume":"159","author":"X Huang","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"02","key":"ref117","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-011-1887-4","article-title":"Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis","volume":"57","author":"M Malaguarnera","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"01","key":"ref118","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","article-title":"Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"110","author":"S R Sharpton","year":"2019","journal-title":"Am J Clin Nutr"},{"issue":"03","key":"ref119","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3945\/ajcn.113.068890","article-title":"Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"99","author":"T Eslamparast","year":"2014","journal-title":"Am J Clin Nutr"},{"issue":"12","key":"ref120","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial","volume":"18","author":"E Manzhalii","year":"2017","journal-title":"J Dig Dis"},{"issue":"05","key":"ref121","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1017\/S0007114517000204","article-title":"Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial","volume":"117","author":"F Mofidi","year":"2017","journal-title":"Br J Nutr"},{"issue":"04","key":"ref122","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial","volume":"58","author":"M R Bomhof","year":"2019","journal-title":"Eur J Nutr"},{"issue":"06","key":"ref123","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"E Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"112309","DOI":"10.1016\/j.foodres.2022.112309","article-title":"Inulin intervention attenuates hepatic steatosis in rats via modulating gut microbiota and maintaining intestinal barrier function","volume":"163","author":"Z Yang","year":"2023","journal-title":"Food Res Int"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ijbiomac.2019.09.007","article-title":"MDG-1, an ophiopogon polysaccharide, restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis","volume":"141","author":"X Wang","year":"2019","journal-title":"Int J Biol Macromol"},{"issue":"08","key":"ref126","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41564-023-01418-7","article-title":"Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid","volume":"8","author":"W Wei","year":"2023","journal-title":"Nat Microbiol"},{"issue":"07","key":"ref127","doi-asserted-by":"crossref","first-page":"e41079","DOI":"10.1371\/journal.pone.0041079","article-title":"Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-diet induced obesity","volume":"7","author":"P Gauffin Cano","year":"2012","journal-title":"PLoS One"},{"issue":"01","key":"ref128","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.celrep.2018.12.028","article-title":"Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids","volume":"26","author":"K Wang","year":"2019","journal-title":"Cell Rep"},{"issue":"01","key":"ref129","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/mi.2016.42","article-title":"Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice","volume":"10","author":"J Y Yang","year":"2017","journal-title":"Mucosal Immunol"},{"issue":"08","key":"ref130","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"C Hill","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"06","key":"ref131","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"35","author":"A Sepideh","year":"2016","journal-title":"J Am Coll Nutr"},{"issue":"10","key":"ref132","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial","volume":"85","author":"V Behrouz","year":"2020","journal-title":"J Food Sci"},{"issue":"09","key":"ref133","first-page":"1090","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial","volume":"15","author":"R Aller","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"07","key":"ref134","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.tjnut.2023.05.019","article-title":"Probiotic supplementation, hepatic fibrosis, and the microbiota profile in patients with nonalcoholic steatohepatitis: a randomized controlled trial","volume":"153","author":"G S Escouto","year":"2023","journal-title":"J Nutr"},{"issue":"01","key":"ref135","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease","volume":"9","author":"S B Ahn","year":"2019","journal-title":"Sci Rep"},{"issue":"01","key":"ref136","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12876-021-01660-5","article-title":"A randomised placebo controlled trial of VSL#3 probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease","volume":"21","author":"P L Chong","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"01","key":"ref137","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"N Kobyliak","year":"2018","journal-title":"J Gastrointestin Liver Dis"},{"issue":"09","key":"ref138","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP BCMC Strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"M H Mohamad Nor","year":"2021","journal-title":"Nutrients"},{"issue":"01","key":"ref139","doi-asserted-by":"crossref","first-page":"e000315","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study","volume":"6","author":"A Duseja","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"issue":"01","key":"ref140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12876-024-03356-y","article-title":"Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Y Pan","year":"2024","journal-title":"BMC Gastroenterol"},{"issue":"02","key":"ref141","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11011-013-9383-5","article-title":"Antibiotics for the treatment of hepatic encephalopathy","volume":"28","author":"K R Patidar","year":"2013","journal-title":"Metab Brain Dis"},{"issue":"07","key":"ref142","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/MEG.0000000000000348","article-title":"Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease","volume":"27","author":"V Gangarapu","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"841132","DOI":"10.3389\/fphar.2022.841132","article-title":"Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids","volume":"13","author":"J Jian","year":"2022","journal-title":"Front Pharmacol"},{"issue":"15","key":"ref144","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.3390\/ijms21155589","article-title":"Effective combination therapy of angiotensin-II receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis","volume":"21","author":"Y Fujinaga","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"10","key":"ref145","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.dld.2022.04.012","article-title":"Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis","volume":"54","author":"M Enomoto","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"10","key":"ref146","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","article-title":"Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot","volume":"30","author":"A Abdel-Razik","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"01","key":"ref147","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/hepr.12904","article-title":"Rifaximin in non-alcoholic steatohepatitis: an open-label pilot study","volume":"48","author":"J FL Cobbold","year":"2018","journal-title":"Hepatol Res"},{"issue":"04","key":"ref148","doi-asserted-by":"crossref","first-page":"e0115521","DOI":"10.1128\/mBio.01155-21","article-title":"Ileal bile acid transporter inhibitor improves hepatic steatosis by ameliorating gut microbiota dysbiosis in NAFLD model mice","volume":"12","author":"M Matsui","year":"2021","journal-title":"MBio"},{"issue":"02","key":"ref149","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"P N Newsome","year":"2020","journal-title":"J Hepatol"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"B A Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"01","key":"ref151","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"S A Harrison","year":"2021","journal-title":"J Hepatol"},{"issue":"09","key":"ref152","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41596-020-0346-0","article-title":"Standardized bacteriophage purification for personalized phage therapy","volume":"15","author":"T Luong","year":"2020","journal-title":"Nat Protoc"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"997587","DOI":"10.3389\/fmicb.2022.997587","article-title":"Genetically engineered bacterium: principles, practices, and prospects","volume":"13","author":"Y Liu","year":"2022","journal-title":"Front Microbiol"},{"issue":"06","key":"ref154","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","article-title":"Promises of microbiome-based therapies","volume":"76","author":"J S Bajaj","year":"2022","journal-title":"J Hepatol"},{"issue":"08","key":"ref155","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gutjnl-2018-317232","article-title":"Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice","volume":"68","author":"T Hendrikx","year":"2019","journal-title":"Gut"},{"issue":"03","key":"ref156","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"T K Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"04","key":"ref157","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"G Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"02","key":"ref158","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmet.2015.07.009","article-title":"Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation","volume":"22","author":"V Tremaroli","year":"2015","journal-title":"Cell Metab"},{"issue":"01","key":"ref159","doi-asserted-by":"crossref","first-page":"2167170","DOI":"10.1080\/19490976.2023.2167170","article-title":"Microbial changes from bariatric surgery alters glucose-dependent insulinotropic polypeptide and prevents fatty liver disease","volume":"15","author":"T S Dong","year":"2023","journal-title":"Gut Microbes"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2438-4383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T23:38:22Z","timestamp":1733355502000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2438-4383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":159,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,12,4]]},"published-print":{"date-parts":[[2024,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2438-4383","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10,10]]},"published":{"date-parts":[[2024,10,10]]}}}